<div>
  <ul>
    <li>
      <p>
        New York-based AI biotech company Envisagenics entered into a multi-year collaboration with big pharma company Bristol-Myers Squibb (BMS) to accelerate the identification of novel oncology targets. The terms and financial details of the agreement have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        The duo will combine Envisagenics&rsquo;s AI platform SpliceCore and BMS&rsquo;s drug development expertise to identify ​​alternative splicing-derived targets to join BMS&rsquo;s existing oncology pipeline.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/envisagenics-announces-research-collaboration-with-bristol-myers-squibb-301687320.html">
      PR Newswire
    </a>
  </p>
</div>


All Updates

Envisagenics partners with Bristol-Myers Squibb to identify oncology targets

Envisagenics receives USD 2 million grant from the National Cancer Institute

Envisagenics secures funding via Series A round